5 結果
CROSS REFERENCE TO RELATED APPLICATION
The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995.
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives.
Nitric Oxide in
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines.
Nitric Oxide in Biology.
The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et